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Thrombinography shows acquired resistance to activated protein C in patients with lupus anticoagulants V6ronique Regnaultl, Suzette B6guin2, DenisWahll-3, Emmanuel de Maistrea, H. Coenraad Henrker2, Thomas Lecomptel-a rH6matologie, EA 3452, Universit6 Henri Poincar6, Nancy, France 2Synapse B.V, Cardiovascular Research Institute, University Maastricht,The Netherlands 3M6decine Interne, and aH6matologie Biologique, CHU de Nancy, France Summary In patients with lupus anticoagulants (LA), acquired resistance to activated protein C (APC) is difficult to demonstrate with clot-based assays due to the presence of the anticoagulant. Via the conversion of a fluorogenic substrate (thrombinography), we monitored the complete process of thrombin formation and decay and its delimitation by the protein C system in eight consecutive LA-patients without anticoagulant therapy and non-carriers of the V Leiden polymorphism.Thrombin generation was trigered in platelet-poor and platelet-rich plasma by recalcification in the presence of a low concentration of tissue factor. In 7 out of 8 patients we observed a long lag-time before the thrombin burst (LA effect) together with a marked inability of Keywords Lupus anticoagulant, acquired APC resistance, thrombin activity, olatelets APC to diminish the thrombin activity.The lag-phase was however prolonged to some degree byAPC.The effects were more outspoken in the presence of phospholipids from Patients' platelets than with added phospholipids. Thrombinography thus demonstrates APC resistance in LA-patients despite the occurrence of long lag-times (clotting times). The amount of thrombin activity generated in the presence of APC could be a better indicator of the thrombotic risk than the moment at which the thrombin burst starts. Thromb Haemost 2003: 89: 208-12 lntroduction Lupus anticoagulants (LA) are the so-called antiphospholipid (auto)antibodies with invitro anticoagulant activity. They delay the burst of thrombin formation and therefbre the moment at which clotting occurs. Paradoxically, thrombosis [the antiphospholipid syndrome (APS) (1)1, may develop in patients with such inhibitory antibodies (2, 3) . Biochemical experiments have shown that these antibodies may interfere with the delimitation of coagulation by APC (4) [also reviewed in (5)], Significant association was reported between lupus-associated APS and a decreased ability of APC to prolong clotting times (6, 7) . Plasma clots when -5 nM of thrombin are fotmed, i.e. at the start of explosive thrombin generation. At that moment>9570 of all thrombin is still to be formed (8) . Such thrombin is presumably still thrombogenic. Heparins, for example, strongly diminish the amount of active thrombin formed without signifrcantly affecting the lag-time of thrombin burst and clot formation (8 We monitored the development of thrombin in clotting plasma via the conversion of a fluorogenic substrate (the thrombinogram) that allows us to observe both the lagtime (clotting time) and the burst and decay of thrombin that follows.
Thrombin generation and the formation and action of APC are cntically dependent upon the composition of the phospholipid surface at which these reactions take place (5) . In order to approach the in vivo conditions, we used the platelets of the patient as the source of phospholipid. In vivo,APC is formed by the activation of protein C by the thrombin-thrombomodulin (TM) complex. We therefore not only investigated the effect of added (exogenous) APC but also that of natural (endogenous) APC, the latter formed during thrombin generation in the presence of added recombinant TM. Table 1 .
Genotyping for FV R506Q was performed as previously described (10) . ELISA Asserachrom APA@ lDiagnostica Stago), which is known to detect antibodies to B2-glycoprotein I, was used to detect "antiphospholipid" antibodies. A first-generation assay for sensitivity to APC was performed as originally described (11) with an automated APTT measurement (AkzoNobel). The sensitivity ratio of a normal pooled plasma was used to derive a normalized ratio (n-APC-SR) for patients.
Course of thrombin activity during clotting Tluombinography was carried out according to the principles described by Hemker et al. (12) . Venous blood was collected on 1/10 volume 0.129 M trisodium citrate and centrifuged to obtain platelet-rich and platelerpoor plasmas (PRP/PPP). Tluombinograms were recorded in citrated plasma to which trace amounts (0.5 pM f.c.) of recombinant human tissue factor (Dade Behring, Marburg, Germany) were added. We used the fluorogenic substrate Z-Gly-Gly-Arg-AMC (Bachem, Bubendorf, Switzerland) (417 pM f.c.), a plate reading fluorometer (Fluoroskan Ascent, Thermolabsystems, Helsinki, Finland) and >140 N/A appropriate softwa.re (Synapse, Maastricht, The Netherlands). The total amount of thrombin activity was assessed as the area under the curve (i.e. the thrombin potential). Recombinant human TM was a kind gift of Asahi (Japan) andAPC was prepared in-house (13) . TM was added at 10 nM and APC at 6;7 and 13.9 nM (f.c.). Thrombin generation was triggered by adding Ca2* (16.1 mM f. c.) . The two normals who had been previously established to be at the upper and lower limits of the interindividual variation of thrombin activity (N = 9) were run in parallel.
Sources of phospholipids PRP (obtained by centrifugation at 190 X g) was adjusted to 150 X 10e platelets/L in all patients but the thrombocytopenic one (LA8, platelet count in PRP of only 117 x l0q/L). Platelet procoagulant phospholipid activity was provoked in three ways: 1: by activation during the thrombin generating process, 2: by freezing and thawing, or 3: by inducing microvesicle fotmation with collagen (Horm, Argene, Varilhes, France) (20 pg/ml., 15 min, 37" C) and centrifuging at 1500 x g to obtain PPP ennched in platelet microvesicles (PPP/PMV).
To PPP centrifuged at 13,000 X g in order to discard microvesicles, synthetic procoagulant phospholipids were added as a mixture of phosphatidyl-serine (20 mole%o), phosphatidylethanolamine (20 mole7a) and phosphatidyl-choline (60 mole7o); (dioleylglycero)phospholipids from Avanti Polar Lipids Inc. (Coger, Pans, France).
Results
As a rule in the plasma of the patients the burst of thrombin generation started later (Table 2 ) and reached a lower peak than in normal plasma. The area under the curve (thrombin potential) was not decreased however (Fig. 1, right panel) .
In normal plasma preparations a decrease in thrombin peak and thrombin potential was seen upon addition of TM and APC (Fig. 1, left panel, Table 2 ). In all patients but one (LA5; Fig. I and Table 2 )TM orAPC hardly diminished these parameters. The lag-phase of the thrombin burst was prolonged to some degree by APC indicating that it was less insensitive to the APC effect than the other parameters (Fig. 1 ). Resistance to TM or APC was observed in the presence of phospholipids from the patients' platelets but not necessarily with added phospholipids (PPP) ( Table 2) . This stresses the importance of studying these reactions in the presence of the natural phospholipids of the patient as brought by their platelets. Patient 1 showed an identical pattern of thrombin generation when measured at a lO-month interval ( Table 2) .
The traditional test for APC-sensitivity failed to give interpretable results due to a prolonged APTT in 4 of our patients ( Table 1 ). The n-APC-SR of patients 3 and 5 fell within the range of values obtained with patients heterozygous for V Leiden polymorphism (Fig. 2 ) and appeared to be misleading since the thrombin potentials in the presence of APC of these 2 patients were affected to a lesser extent ( Table 2) . Conversely the n-APC-SR of patient LA2 fell close to the median for non LA, non V-Leiden patients (Fig. 2) , but thrombinography clearly showed APC resistance ( Table 2 ).
Discussion
Our results show that in LA-patients abnormally high thrombin activity can be detected in an experimental setup approaching the conditions prevailing invivo, i.e. mrnimally diluted plasma, natural (platelet) procoagulant phospholipids and the presence of an active protein C system. In contrast to traditional clotting times, in our test the course of thrombin-concentration after clotting are recorded. In PRP of both notmals and patients the presence ofplatelets induces a resistance to APC that is seen to a lesser extent with frozen-thawed platelets or platelet microvesicles. The effect of TM seems much less subject to this phenomenon (results with normals, Table 2 ). At present we have no exolanation for this observalion. Table 2 : Thrombinography.Thrombin activity was recorded in the absence or presence of an active protein C system. Lag-time to burst of thrombin generation is only given in its absence. As expected it is short when procoagulant phospholipids are made available as soon as the reaction starts (frozen-thawed PRP and PPP/PMV). Inhibition of thrombin activity in the presence of TM or APC is expressed as percentage of the uninhibited area under the curve.The standard deviation in the uninhibited plasma being l3%, inhibitions <13% were considered not significant (_).The figures in italics are out of the normal range. PRP = fresh platelet-rich l$T:;::nt"V = platelet microvesicles in platelet-poor plasma; PPP = platelet-poor plasma centrifuged at 13,000 x g. N/D: Figure 2 : Normalized APC sensitivity ratios. The original APC resistance clot-based test was performed with plasma of 5l4 patients with thrombotic events but with neither oral anticoagulant therapy nor lupus anticoagulant (grey circles) and with plasma of 7 out of the 8 study patients (black circles corresponding to the 3 patients for whom the n-APC-SR was deemed applicablesee Table | 2t2 Regnault, et al. The apparent paradox of prolonged clotting times accompanying thrombophilia disappears if one assumes that not the lag-time to thrombin burst but rather the amount of thrombin formed in the presence of the APC-system is the parameter that indicates thrombotic risk. This is in line with the observatioris that no shortening of clotting times is usually seen in most prothrombotic states and that antithrombotic effect of heparin is not necessarily accompanied by lengthening of TF-induced clotting times (14) .
The combination of APC resistance and delay of thrombin burst could be explained by assuming that LA inhibits the activation of factors V and VIII by (meizo)thrombin as well as their inactivation by APC. Both processes occur at the phospholipid surface and thus may be thought to be influenced by phospholipid-dependent antibodies.
An inhibitory effect on thrombin-induced, TM-dependent protein C activation has been reported in LA-patients (15) . This seems less likely in the present patients because then thrombin generation would have been resistant to TM but not to APC.
The degree of inhibition of the APC-effect in our patients is on the whole much higher than that seen in subjects homozygous for the factorV Leiden polymorphism, where about half of the activity of the APC-system remains (results to be published). This is in keeping with the risk of recunent thrombosis over 6 years reported in clinical settings: LA:69V0 (16), factor V Leiden 39Vo (11) .
Our results suggest that thrombin activity might be a better indicator of thrombotic risk than clotting times are. Our study was not designed, however, to establish conelations with clinical or laboratory data. Because the cunent method has been completely automated and allows the parallel measurement of up to 48 samples (see www.thrombin.com) it is suited for the larger clinical studies that are required for this purpose. It might also serve to chose and dose antithrombotic therapy in LA patients, at the present time a very challenging issue (18, 19) .
